Last reviewed · How we verify

NCT05442229

A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years

Status unknown Last updated 1 July 2022
What this trial tests

trial testing establish a new Chinese children's speech and language norm in Mental Retardation in 5,744 participants. Status unknown.

Timeline
1 July 2022
Primary endpoint
28 February 2023
28 February 2023

Quick facts

Lead sponsorTongji Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment5,744
Start date1 July 2022
Primary completion28 February 2023
Estimated completion28 February 2023

Drugs / interventions tested

Conditions studied

Sponsor

Tongji Hospital

Who can join

Adults 2 to 6, any sex, with Mental Retardation or Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish a new Chinese children's speech and language norm by obtaining the latest data of speech and language development of children aged 2 \~ 6 from different regions in China. At the same time, the overall development level and group differences of speech and language in Chinese children aged 2 to 6 years, and the influencing factors of speech and language development in Chinese children aged 2 to 6 years were also discussed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mental Retardation

Currently open trials in the same condition.

Other Tongji Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05442229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing